Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells

被引:25
作者
Sun, XJ [1 ]
Gulyás, M [1 ]
Hjerpe, A [1 ]
Dobra, K [1 ]
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Dept Lab Med, Div Pathol, S-14186 Huddinge, Sweden
关键词
mesothelionia cells; proteasome proteasome inhibitors; apoptosis;
D O I
10.1016/j.canlet.2005.02.022
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Malignant mesothelioma is an increasingly common tumor With an almost 100% mortality rate. It is refractory to conventional treatment. We have previously shown with SSH and microarray that the mRNA expression level of proteasome is higher in epithelioid mesothelioma cell lines than in sarcomatoid ones. This study evaluates the differential apoptotic effect of proteasome inhibitors on both of these mesothelioma sub-lines. Proteasome inhibitors show substantial anti-tumor activity in some tumor cells in vitro and in vivo, but the effects on mesothelioma cells has not been Studied. The viability of mesothelioma cells was reduced in a dose- and time-dependent manner by the proteasome inhibitors tested: PSI was effective with a low close, but higher concentrations were needed for calpain inhibitor 1. The epithelioid mesothelioma cells are more sensitive to the inhibitors than the sarcomatoid ones, their IC50 after 24 h of treatment with PSI being 4 and 16 mu m, respectively. Other mesothelioma cell lines show similar sensitivity. PSI seemed to decrease mesothelioma viability by inducing apoptosis, as verified by cell morphology, Western blotting analysis of caspase 3 cleavage, and flow-cytometric analysis. In conclusion, PSI, a representative agent that reduces viability and induces apoptosis of mesothelioma cells, might be useful in the treatment of patients with mesothelioma, especially of epithelioid phenotype. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:161 / 169
页数:9
相关论文
共 30 条
[1]   Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells [J].
Adachi, M ;
Zhang, YB ;
Zhao, XD ;
Minami, T ;
Kawamura, R ;
Hinoda, Y ;
Imai, K .
CLINICAL CANCER RESEARCH, 2004, 10 (11) :3853-3862
[2]   THE UBIQUITIN-PROTEASOME PROTEOLYTIC PATHWAY [J].
CIECHANOVER, A .
CELL, 1994, 79 (01) :13-21
[3]  
Cusack JC, 2001, CANCER RES, V61, P3535
[4]   The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-α-initiated apoptosis [J].
Delic, J ;
Masdehors, P ;
Ömura, S ;
Cosset, JM ;
Dumont, J ;
Binet, JL ;
Magdelénat, H .
BRITISH JOURNAL OF CANCER, 1998, 77 (07) :1103-1107
[5]   Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells [J].
Dewson, G ;
Snowden, RT ;
Almond, JB ;
Dyer, MJS ;
Cohen, GM .
ONCOGENE, 2003, 22 (17) :2643-2654
[6]   Inhibition of proteasome function induces programmes cell death in proliferating endothelial cells [J].
Drexler, HCA ;
Risau, W ;
Konerding, MA .
FASEB JOURNAL, 2000, 14 (01) :65-77
[7]   A NOVEL CHYMOTRYPSIN-LIKE COMPONENT OF THE MULTICATALYTIC PROTEINASE COMPLEX OPTIMALLY ACTIVE AT ACIDIC PH [J].
FIGUEIREDOPEREIRA, ME ;
CHEN, WE ;
YUAN, HM ;
WILK, S .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1995, 317 (01) :69-78
[8]   NEW INSIGHTS INTO PROTEASOME FUNCTION - FROM ARCHAEBACTERIA TO DRUG DEVELOPMENT [J].
GOLDBERG, AL .
CHEMISTRY & BIOLOGY, 1995, 2 (08) :503-508
[9]   FUNCTIONS OF THE PROTEASOME - THE LYSIS AT THE END OF THE TUNNEL [J].
GOLDBERG, AL .
SCIENCE, 1995, 268 (5210) :522-523
[10]   Preferential induction of apoptosis for primary human leukemic stem cells [J].
Guzman, ML ;
Swiderski, CF ;
Howard, DS ;
Grimes, BA ;
Rossi, RM ;
Szilvassy, SJ ;
Jordan, CT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (25) :16220-16225